Arkolith/Insider Trading/JANX/Form 4

Meyer Andrew Hollman

Chief Business OfficerJanux Therapeutics, Inc. (JANX) · full profile →Form 4 · filed May 2, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$107K
Net Open-Market Flow
-$107K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 1, 2025Sell(S)400$32.60$13K82K
May 1, 2025Sell(S)3K$31.95$94K83K
May 1, 2025Option exercise(M)3K$4.21$14K85K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 1, 2025Option exercise(M)3K—$087K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-011874) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML